Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
35.29
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
↗
January 03, 2025
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals.
Via
Chartmill
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
December 17, 2024
Via
ACCESSWIRE
NASDAQ:HRMY is not too expensive for the growth it is showing.
↗
December 16, 2024
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing.
Via
Chartmill
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
December 16, 2024
Via
ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
December 13, 2024
Via
ACCESSWIRE
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
↗
October 30, 2024
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders.
Via
Benzinga
Analyst Expectations For Harmony Biosciences's Future
↗
October 29, 2024
Via
Benzinga
Earnings Outlook For Harmony Biosciences
↗
October 28, 2024
Via
Benzinga
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
↗
October 02, 2024
Via
Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
↗
October 29, 2024
HRMY earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
↗
October 29, 2024
The company is focused on developing its pipeline of sleep and epilepsy drugs.
Via
Investor's Business Daily
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
↗
September 10, 2024
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.
Via
Benzinga
Unveiling 6 Analyst Insights On Harmony Biosciences
↗
September 10, 2024
Via
Benzinga
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
↗
August 06, 2024
HRMY earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Analyst Expectations For Harmony Biosciences's Future
↗
August 06, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
↗
June 21, 2024
Via
Benzinga
Key Takeaways From Harmony Biosciences Analyst Ratings
↗
April 30, 2024
Via
Benzinga
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
↗
March 28, 2024
Via
Benzinga
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
↗
August 06, 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
August 06, 2024
From
Harmony Biosciences
Via
GlobeNewswire
7 Cheap Biotech Stocks With Major Upside Potential
↗
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
↗
July 01, 2024
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
↗
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
↗
May 14, 2024
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via
Benzinga
Topics
Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
↗
April 30, 2024
HRMY earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
↗
April 30, 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
↗
April 30, 2024
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with...
Via
Benzinga
Topics
Earnings
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
April 30, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Updates: HRMY, MELI, SWAV
↗
February 28, 2024
Another day, another slew of quarterly update reports for our followed stocks.
Via
Talk Markets
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
↗
February 22, 2024
HRMY earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today